natgillin/translations-raw huggingface dataset:
Some patients however may have systemic pazopanib exposure greater than what has been observed after administration of 800 mg pazopanib alone.
A pri nekaterih bolnikih je lahko sistemska izpostavljenost pazopanibu večja, kot je bila zabeležena po uporabi 800 mg pazopaniba samega.
The OS results are subject to potential bias as 54% of patients in the placebo arm also received pazopanib in the extension part of this study following disease progression.
Rezultati celokupnega preživetja so lahko pristranski, ker je 54 % bolnikov iz skupine s placebom v podaljšanju te študije po napredovanju bolezni prav tako prejemalo pazopanib.
If you are going to have an operation
Če imate predviden kirurški poseg
Exposure at a 200 mg dose is markedly reduced, though highly variable, in these patients, with values considered insufficient to obtain a clinically relevant effect.
Izpostavljenost po odmerku 200 mg je pri teh bolnikih sicer zelo variabilna in bistveno nižja, dosežene vrednosti ocenjujejo kot nezadostne za doseganje klinično pomembnega učinka.
High blood pressure and Votrient
Visok krvni tlak in zdravilo Votrient
Ninety-eight percent (98%) of subjects received prior doxorubicin, 70% prior ifosfamide, and 65% of subjects had received at least three or more chemotherapeutic agents prior to study enrolment.
Osemindevetdeset odstotkov (98 %) preiskovancev je predhodno prejemalo doksorubicin, 70 % ifosfamid in 65 % preiskovancev je pred vključitvijo v študijo prejelo vsaj tri ali več kemoterapevtskih sredstev.
If the concomitant administration of an H2-receptor antagonist is medically necessary, pazopanib should be taken without food at least 2 hours before or at least 10 hours after a dose of an H2-receptor antagonist.
Če je sočasna uporaba antagonista receptorjev H2 medicinsko potrebna, je treba pazopanib vzeti brez hrane vsaj 2 uri pred ali vsaj 10 ur po odmerku antagonista receptorjev H2.
See section 4.4 for liver monitoring and dose modification for patients with drug-induced hepatotoxicity.
Glejte poglavje 4.4 za spremljanje jeter in prilagoditev odmerka pri bolnikih z medikamentozno povzročenimi hepatotoksičnimi učinki.
OS = overall survival * Overall survival for the respective STS histological subgroups (leiomyosarcoma, synovial sarcoma and “Other” STS) should be interpreted with caution due to the small number of subjects and wide confidence intervals
OS = celokupno preživetje * Celokupno preživetje za zadevne histološke podskupine STS (leiomiosarkom, sinovijski sarkom in "drugi" STS) je treba zaradi majhnega števila preiskovancev in širokih intervalov zaupanja tolmačiti previdno.
Table 3 Treatment-related adverse reactions reported in STS studies (n=382)
Preglednica 3: Z zdravljenjem povezani neželeni učinki, o katerih so poročali v študijah pri STS (n = 382)
PFS Overall ITT
PFS Celokupni ITT
Liver test values
Vrednosti jetrnih testov
Votrient is used in adults to treat: - kidney cancer that is advanced or has spread to other organs.
Zdravilo Votrient se uporablja pri odraslih za zdravljenje: - raka ledvic, ki je napredoval ali se je razširil v druge organe.
Other medicines and Votrient
Druga zdravila in zdravilo Votrient
If the concomitant use of a proton-pump inhibitor (PPI) is medically necessary, it is recommended that the dose of pazopanib be taken without food once daily in the evening concomitantly with the PPI.
Če je sočasna uporaba zaviralcev protonske črpalke (PPI - proton-pump inhibitor) medicinsko potrebna, je odmerek pazopaniba priporočljivo vzeti brez hrane, enkrat na dan zvečer, obenem s PPI.
If the clot breaks off, it may travel to your lungs and this may be life threatening or even fatal.
Če se strdek odtrga, lahko potuje v pljuča; to je lahko smrtno nevarno ali celo usodno.
Symptoms include shortness of breath or cough that will not go away.
Med simptomi sta težko dihanje ali kašelj, ki ne mine.
P value (one-sided)
P vrednost (enostranski test)
OS Overall ITT
OS Celokupni ITT
Results indicate that less than 4% of an orally administered pazopanib dose is excreted in the urine as pazopanib and metabolites.
Rezultati kažejo, da se manj kot 4 % peroralno uporabljenega odmerka pazopaniba izloči z urinom v obliki pazopaniba in presnovkov.
The majority of these cases describe mucositis f Frequency is based on laboratory value tables from VEG110727 (N=240).
Večina teh primerov opisuje mukozitis f Pogostnost temelji na preglednicah laboratorijskih vrednosti iz VEG110727 (n = 240).
Perforation and fistula
Perforacija in fistula
The four principle pazopanib metabolites account for only 6% of the exposure in plasma.
Štirje glavni presnovki pazopaniba predstavljajo le 6 % izpostavljenosti v plazmi.
Since vascular endothelial growth factor (VEGF) inhibitors may impair wound healing, treatment with pazopanib should be stopped at least 7 days prior to scheduled surgery.
Ker lahko zaviralci žilnega endotelnega rastnega faktorja (VEGF - vascular endothelial growth factor) vplivajo na celjenje ran, je treba zdravljenje s pazopanibom prekiniti vsaj 7 dni pred načrtovanim kirurškim posegom.
Votrient has no or negligible influence on the ability to drive and use machines.
Zdravilo Votrient nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
When post-weaning rats were dosed from day 21 post partum to day 62 post partum, toxicological findings were similar to adult rats at comparable exposures.
Ko so podgane po prenehanju dojenja pazopanib prejemale od 21. do 62. postpartalnega dneva, so bile toksikološke ugotovitve podobne kot pri odraslih podganah pri primerljivih izpostavljenostih.
Renal cell carcinoma (RCC)
Karcinom ledvičnih celic (RCC)
VEG108844 achieved its primary endpoint of PFS and demonstrated that pazopanib was non-inferior to sunitinib, as the upper bound of the 95% CI for the hazard ratio was less than the protocol-specified non-inferiority margin of 1.25.
Študija VEG108844 je dosegla primarni opazovani dogodek preživetja brez napredovanja in je pokazala, da je pazopanib neinferioren sunitinibu, ker je bila zgornja meja 95 % IZ za razmerje ogroženosti manjša od v protokolu opredeljene meje neinferiornosti 1,25.
Four of the 15 subjects had full recovery (within 5% of baseline) and 5 had partial recovery (within the normal range, but >5% below baseline).
Štirje od 15 preiskovancev so povsem okrevali (vrednost znotraj 5 % od izhodiščne), 5 pa jih je okrevalo delno (vrednost znotraj normalnega območja, vendar > 5 % manj od izhodiščne).
Patients should be monitored until return to Grade 1 or baseline.
Bolnike je treba nadzirati, dokler se vrednosti ne vrnejo na stopnjo 1 ali izhodiščno vrednost.
The safety and pharmacokinetics of pazopanib in patients with moderate to severe heart failure or those with a below normal left ventricular ejection fraction (LVEF) have not been studied.
Varnost in farmakokinetika pazopaniba pri bolnikih z zmernim do hudim srčnim popuščanjem in bolnikih z iztisnim deležem levega prekata (LVEF - left ventricular ejection fraction), nižjim od normalnega, nista raziskani.
Glaxo Operations UK Ltd (trading as Glaxo Wellcome Operations), Priory Street, Ware, Hertfordshire, SG12 0DJ, United Kingdom.
Glaxo Operations UK Ltd (trading as Glaxo Wellcome Operations), Priory Street, Ware, Hertfordshire, SG12 0DJ, Velika Britanija
Votrient can raise your blood pressure.
Zdravilo Votrient lahko zviša krvni tlak.
However, the UGT1A1 genotype was not always predictive of the effect of pazopanib on SN-38 disposition.
Vendar genotip UGT1A1 ni bil vedno napovednik vpliva pazopaniba na odstranjevanje SN-38.
Prior anthracycline therapy may be a risk factor for cardiac dysfunction.
Predhodno zdravljenje z antraciklini je lahko dejavnik tveganja za moteno delovanje srca.
You may need extra tests to check that your heart and liver are working properly.
Zdravnik bo morda moral opraviti dodatne preiskave, s katerimi bo preveril delovanje srca in jeter.
Based on in vitro IC50 and in vivo plasma Cmax values, pazopanib metabolites GSK1268992 and GSK1268997 may contribute to the net inhibitory effect of pazopanib towards BCRP.
Glede na vrednosti IC50 in vitro in vrednosti Cmax v plazmi in vivo lahko presnovka pazopaniba GSK1268992 in GSK1268997 pripomoreta k neto zaviralnemu vplivu pazopaniba na BCRP.
Concomitant use of pazopanib and simvastatin increases the incidence of ALT elevations.
Sočasna uporaba pazopaniba in simvastatina poveča incidenco zvišanj ALT.
Male patients (including those who have had vasectomies) who have partners who are either pregnant or who could become pregnant (including those who use other methods of contraception) should use condoms during sexual intercourse while taking Votrient and for at least 2 weeks after the last dose.
Bolniki moškega spola (tudi tisti, ki so imeli vazektomijo), katerih partnerka je noseča ali lahko zanosi (kar vključuje tudi tiste partnerke, ki uporabljajo še druge metode kontracepcije), morajo v času jemanja zdravila Votrient in še najmanj 2 tedna po tem, ko vzamejo zadnji odmerek, pri spolnih odnosih uporabljati kondom.
Reproductive, fertility and teratogenic effects
Vpliv na sposobnost razmnoževanja, plodnost in teratogeni učinki
What Votrient is and what it is used for What you need to know before you take Votrient How to take Votrient
Kaj je zdravilo Votrient in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Votrient Kako jemati zdravilo Votrient Možni neželeni učinki
Blood pressure should be monitored and managed promptly using a combination of anti-hypertensive therapy and dose modification of pazopanib (interruption and re-initiation at a reduced dose based on clinical judgement) (see sections 4.2 and 4.8).
Krvni tlak je treba kontrolirati in ga takoj urejati s kombinacijo antihipertenzivnih zdravil in prilagoditvijo odmerka pazopaniba (prekinitev in ponovna uvedba v zmanjšanem odmerku po klinični presoji) (glejte poglavji 4.2 in 4.8).
Other key eligibility criteria of the VEG110727 study were: histological evidence of high or intermediate grade malignant STS and disease progression within 6 months of therapy for metastatic disease, or recurrence within 12 months of (neo) -/adjuvant therapy.
Druga ključna merila primernosti za študijo VEG110727 so bila: histološko dokazan maligni STS intermediarne ali visoke stopnje in napredovanje bolezni v 6 mesecih po začetku zdravljenja metastatske bolezni, ali ponovitev v 12 mesecih po začetku (neo)-/adjuvantnega zdravljenja.
Elevated blood pressure levels (systolic blood pressure ≥150 mm Hg or diastolic blood pressure ≥100 mm Hg) occurred early in the course of treatment (approximately 40% of cases occurred by day 9 and approximately 90% of cases occurred in the first 18 weeks).
Stopnje zvišanega krvnega tlaka (sistolični krvni tlak ≥ 150 mm Hg ali distolični krvni tlak ≥ 100 mm Hg) so se pojavile kmalu po uvedbi zdravljenja (v približno 40 % primerov se je pojavila do 9. dneva zdravljenja in v približno 90 % primerov se je pojavila v prvih 18 tednih po uvedbi zdravljenja).
Votrient is a type of medicine called a protein kinase inhibitor.
Zdravilo Votrient spada v skupino zdravil, imenovano zaviralci protein-kinaze.
Adults The recommended dose of pazopanib for the treatment of RCC or STS is 800 mg once daily.
Odrasli Priporočeni odmerek pazopaniba za zdravljenje RCC ali STS je 800 mg enkrat na dan.
The safe use of pazopanib during breast-feeding has not been established.
Varnost uporabe pazopaniba med dojenjem ni bila dokazana.
In a Phase II study of 225 patients with locally recurrent or metastatic clear cell renal cell carcinoma, objective response rate was 35% and median duration of response was 68 weeks, as per independent review.
V študiji Faze II, v katero je bilo vključenih 225 bolnikov z lokalno ponovitvijo ali metastatskim čistim karcinomom ledvičnih celic, je neodvisna presoja pokazala, da je bil objektivni delež odziva 35 %, mediana vrednost trajanja odziva pa 68 tednov.
No formal studies of the effect of pazopanib on wound healing have been conducted.
Formalne študije o vplivu pazopaniba na celjenje ran niso bile izvedene.
The active metabolite of irinotecan, SN-38, is a substrate for OATP1B1 and UGT1A1.
Aktivni presnovek irinotekana, SN-38, je substrat OATP1B1 in UGT1A1.
If the potential benefit of reinitiating pazopanib treatment is considered to outweigh the risk for hepatotoxicity, then reintroduce pazopanib at a reduced dose of 400 mg daily and perform serum liver tests weekly for 8 weeks.
Če je pričakovana korist ponovne uvedbe zdravljenja s pazopanibom večja od tveganja za pojav hepatotoksičnih učinkov, je treba uvesti zdravljenje s pazopanibom z nižjim odmerkom 400 mg na dan in opravljati serumske jetrne teste vsak teden 8 tednov.
It is not yet known how well it works in this age group.
V tej starostni skupini delovanje zdravila še ni popolnoma znano.
Tell your doctor if you notice significant weight gain or tiredness.
Obvestite zdravnika, če opazite znatno povečanje telesne mase ali utrujenost.
Daily dosing results in 1.23- to 4-fold increase in AUC0-T.
Pri dnevnem odmerjanju se vrednost AUC0-T poveča za 1,23-krat do 4-krat.
For patients who responded to treatment, the median time to response was 11.9 weeks and the median duration of response was 58.7 weeks as per independent review (VEG105192).
Neodvisna presoja je pokazala, da je bila pri bolnikih, ki so se odzvali na zdravljenje, mediana vrednost časa do odziva 11,9 tedna, mediana vrednost trajanja odziva pa 58,7 tedna (VEG105192).
Laboratory abnormalities were reported as adverse events less frequently by investigators than as indicated by laboratory value tables.
Laboratorijske nepravilnosti so kot neželene učinke raziskovalci opisali manj pogosto, kot kažejo preglednice laboratorijskih vrednosti.
Effect of concomitant use of pazopanib and simvastatin
Vpliv sočasne uporabe pazopaniba in simvastatina
Liver function should be monitored in all subjects receiving pazopanib, regardless of genotype or age (see section 5.1).
Delovanje jeter je treba spremljati pri vseh osebah, ki prejemajo pazopanib, ne glede na njihov genotip in starost (glejte poglavje 5.1).
Effects of pazopanib on other medicinal products
Vpliv pazopaniba na druga zdravila
There are limited data on the use of pazopanib in patients aged 65 years and older.
Podatkov o uporabi pazopaniba pri bolnikih, starih 65 let in starejših, je malo.
The following tumour types were not eligible:
Neprimerni so bili naslednji tipi tumorjev:
Synovial sarcoma subgroups* N = 25
Podskupine sinovijskega sarkoma n = 25
Infections occurring while you take Votrient may possibly become serious.
Okužbe, ki se pojavijo v času jemanja zdravila Votrient, se lahko razvijejo v resne okužbe.
Concomitant use of pazopanib and simvastatin increases the risk of ALT elevations (see section 4.5) and should be undertaken with caution and close monitoring.
Sočasna uporaba pazopaniba in simvastatina poveča tveganje za zvišanje ALT (glejte poglavje 4.5), zato je treba to kombinacijo uporabljati previdno in ob natančnem nadzoru.
PRES/RPLS can present with headache, hypertension, seizure, lethargy, confusion, blindness and other visual and neurological disturbances, and can be fatal.
PRES/RPLS se lahko pokaže z glavobolom, hipertenzijo, konvulzijami, letargijo, zmedenostjo, slepoto in drugimi motnjami vida oziroma nevrološkimi motnjami ter se lahko konča smrtno.
Pazopanib should not be used during pregnancy unless the clinical condition of the woman requires treatment with pazopanib.
Pazopaniba se med nosečnostjo ne sme uporabljati, razen če klinično stanje bolnice zahteva zdravljenje s pazopanibom.
Decreased appetite and anorexia f Cardiac dysfunction, left ventricular dysfunction, cardiac failure and restrictive cardiomyopathy g
Zmanjšan apetit in neješčnost (anoreksija) f Disfunkcija srca, disfunkcija levega prekata, srčno popuščanje in restriktivna kardiomiopatija g
It should be taken without food, at least one hour before or two hours after a meal (see section 5.2).
Jemati ga je treba brez hrane, vsaj eno uro pred ali dve uri po jedi (glejte poglavje 5.2).
Patients were stratified by the factors of WHO performance status (WHO PS) (0 or 1) at baseline and the number of lines of prior systemic therapy for advanced disease (0 or 1 vs. 2+).
Bolnike so stratificirali po faktorjih stanja zmogljivosti po Svetovni zdravstveni organizaciji (WHO PS) (0 ali 1) izhodiščno in po številu linij predhodnega sistemskega zdravljenja za napredovalo bolezen (0 ali 1 v prim.
The type of medicine that you are taking to reduce your stomach acid (e.g. proton pump inhibitor, H2 antagonists or antacids) may affect how Votrient is taken.
Določena vrsta zdravil, ki se uporabljajo za zmanjšanje želodčne kisline (npr. zaviralci protonske črpalke, antagonisti H2 ali antacidi) lahko vplivajo na to, kako se jemlje zdravilo Votrient.
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benigne, maligne in neopredeljene neoplazme (vključno s cistami in polipi)
PFS Overall Median (months) (95% CI)
PFS Skupaj Mediana (meseci) (95 % IZ)
Median (months)
Mediana (meseci)
Other observed effects include body weight loss, diarrhoea and/or morbidity that were either secondary to local gastrointestinal effects caused by high local mucosal medicinal product exposure (monkeys) or pharmacological effects (rodents).
Drugi opaženi učinki so bili: zmanjšanje telesne mase, driska in/ali morbidnosti, ki so bile bodisi sekundarnega porekla zaradi lokalnih gastrointestinalnih učinkov, povzročenih z visoko lokalno izpostavljenostjo sluznice zdravilu (opice) ali farmakoloških učinkov (glodavci).
Pazopanib should be discontinued if there is evidence of hypertensive crisis or if hypertension is severe and persists despite anti-hypertensive therapy and pazopanib dose reduction.
Zdravljenje s pazopanibom je treba ukiniti v primeru hipertenzivne krize ali če je hipertenzija huda in traja kljub antihipertenzivnemu zdravljenju in znižanju odmerka pazopaniba.
In clinical studies with pazopanib, events of hypertension including newly diagnosed symptomatic episodes of elevated blood pressure (hypertensive crisis) have occurred.
V kliničnih študijah s pazopanibom so se pojavili primeri hipertenzije, vključno z na novo diagnosticiranimi simptomatskimi epizodami zvišanega krvnega tlaka (hipertenzivna kriza).
In VEG108844, patients (N = 1110) with locally advanced and/or metastatic RCC who had not received prior systemic therapy, were randomised to receive either pazopanib 800 mg once daily continuously or sunitinib 50 mg once daily in 6-week cycles of dosing with 4 weeks on treatment followed by 2 weeks without treatment.
V VEG108844 so bolnike (N = 1110) z lokalno napredovalim in/ali metastatskim RCC, ki predhodno niso prejemali sistemskega zdravljenja, randomizirali na prejemanje ali pazopaniba 800 mg enkrat na dan neprekinjeno ali sunitiniba 50 mg enkrat na dan v 6-tedenskih ciklusih, ki so obsegali 4 tedne zdravljenja in 2 tedna brez zdravljenja.
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo, tudi če ste ga dobili brez recepta, vključno z zdravili rastlinskega izvora.
Overall Survival Median (months) (95% CI)
Celokupno preživetje Mediana (meseci) (95 % IZ)
The 200 mg tablets also contain iron oxide red (E172).
200 mg filmsko obložene tablete vsebujejo tudi rdeči železov oksid (E172).
g Cardiac dysfunction events - includes Left ventricular dysfunction, Cardiac failure and Restrictive cardiomyopathy h Frequency is based on adverse events reported by investigators.
g Dogodki motenega delovanja srca - vključuje moteno delovanje levega prekata, srčno popuščanje in restriktivno kardiomiopatijo h Pogostnost temelji na neželenih učinkih, o katerih so poročali raziskovalci.
The decision to resume pazopanib after surgery should be based on clinical judgement of adequate wound healing.
Odločitev o nadaljevanju zdravljenja s pazopanibom po opravljenem kirurškem posegu je treba sprejeti na osnovi klinične presoje ustreznosti celjenja rane.
Effects included reduced female fertility, increased pre- and post-implantation loss, early resorptions, embryo lethality, decreased foetal body weight and cardiovascular malformation.
Učinki so obsegali, zmanjšano plodnost samic, pogostejše izgube pred in po nidaciji, zgodnje resorpcije, smrtnost zarodkov, zmanjšano telesno maso zarodkov in kardiovaskularne malformacije.
Binding of pazopanib to human plasma protein in vivo was greater than 99% with no concentration dependence over the range of 10-100 g/ml.
Vezava pazopaniba na humane plazemske proteine je in vivo večja od 99 % in v razponu od 10100 g/ml ni odvisna od koncentracije.
Don't stop Votrient without advice Take Votrient for as long as your doctor recommends.
Zdravila Votrient ne smete nehati jemati brez nasveta zdravnika Zdravilo Votrient morate jemati tako dolgo, kot vam je to predpisal zdravnik.
The following tumour types were eligible:
Primerni so bili naslednji tipi tumorjev:
Posterior reversible encephalopathy syndrome (PRES)/Reversible posterior leukoencephalopathy syndrome (RPLS)
Sindrom posteriorne reverzibilne encefalopatije (PRES - Posterior reversible encephalopathy syndrome)/reverzibilni posteriorni levkoencefalopatski sindrom (RPLS - Reversible posterior leukoencephalopathy syndrome)
In vitro studies with human liver microsomes showed that pazopanib inhibited CYP enzymes 1A2, 3A4, 2B6, 2C8, 2C9, 2C19, and 2E1.
Študije in vitro s humanimi jetrnimi mikrosomi so pokazale, da pazopanib zavira encime CYP 1A2, 3A4, 2B6, 2C8, 2C9, 2C19 in 2E1.
Tabulated list of adverse reactions
Tabelirani seznam neželenih učinkov
Disease characteristics at initial diagnosis and at screening were balanced between the treatment arms with the majority of patients having clear cell histology and Stage IV disease.
Značilnosti bolezni ob uvodni diagnozi in ob presejanju so bile med terapevtskima skupinama uravnotežene; večina bolnikov je imela svetlocelično histologijo in bolezen v IV. stadiju.
Clinical pharmacology studies, using pazopanib 800 mg once daily, have demonstrated that pazopanib does not have a clinically relevant effect on the pharmacokinetics of caffeine (CYP1A2 probe substrate), warfarin (CYP2C9 probe substrate), or omeprazole (CYP2C19 probe substrate) in cancer patients.
Klinične farmakološke študije z uporabo pazopaniba v odmerku 800 mg enkrat na dan so pokazale, da pazopanib pri bolnikih z rakom nima klinično pomembnih učinkov na farmakokinetiko kofeina (preiskovani substrat za CYP1A2), varfarina (preiskovani substrat za CYP2C9) ali omeprazola (preiskovani substrat za CYP2C19).
Investigated dose
Raziskovani odmerek
One of these metabolites inhibits the proliferation of VEGF-stimulated human umbilical vein endothelial cells with a similar potency to that of pazopanib, the others are 10- to 20-fold less active.
Eden od teh presnovkov zavira z žilnim endotelijskim rastnim faktorjem (VEGF) stimulirano proliferacijo humanih endotelnih celic umbilikalne vene z enako jakostjo kot pazopanib, ostali pa so za od 10- do 20-krat manj aktivni.
The median duration of follow-up of subjects (defined as date of randomisation to date of last contact or death) was similar for both treatment arms (9.36 months for placebo [range 0.69 to 23.0 months] and 10.04 months for pazopanib [range 0.2 to 24.3 months].
Mediano trajanje spremljanja preiskovancev (opredeljeno kot obdobje od datuma randomizacije do datuma zadnjega stika ali smrti) je bilo v obeh terapevtskih skupinah podobno (9,36 meseca za placebo [razpon od 0,69 do 23,0 meseca] in 10,04 meseca za pazopanib [razpon od 0,2 do 24,3 meseca]).
These were reported as adverse events less frequently by investigators than as indicated by laboratory value tables.
Raziskovalci so te neželene učinke opisali manj pogosto, kot kažejo preglednice laboratorijskih vrednosti.
You must look out for certain symptoms while you are taking Votrient to reduce the risk of any problems.
Med zdravljenjem z zdravilom Votrient morate biti še posebej pozorni na nekatere simptome, da bi se tako zmanjšalo tveganje za pojav kakršnih koli resnejših težav.